Rigel's novel RA candidate to progress to Phase III
This article was originally published in Scrip
Executive Summary
Rigel Pharmaceuticals' novel oral rheumatoid arthritis candidate R788 (fostamatinib disodium) has succeeded in a Phase IIb trial, and the company is now hoping to find a partner to progress the drug into Phase III.